focus -WSS

focus

author：entertainment 2025-09-28 22:10:36 - browse：6

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Flagship Pioneering startup Sonata Therapeutics lays off 21

hotspot

knowledge

WSS

Reporting on presidential health from Reagan to Trump and Biden

Researchers tackle phage therapy hurdles for wider adoption

As AI regulations shape up, health tech startups beg for clarity

Weight loss drugs aren’t covered by Obamacare. That may change

Use wet bulb globe temperature, not heat index, to protect workers

Reporting on presidential health from Reagan to Trump and Biden

knowledge

focus

focus

How one medical school became remarkably diverse

After gene therapy, two congenitally deaf children hear for the first time

Affirmative action in medical school literally saved lives

As AI regulations shape up, health tech startups beg for clarity

Continuity nursing helped my family in our darkest PICU moments

Sanofi strikes deal with Novavax, boosting the vaccine maker

Virginia high school admissions case could be legal follow

Researchers on aging grapple with how to calculate biological age

Virginia high school admissions case could be legal follow

Medicare Advantage enrollment grows 7.1% to 33.4 million people

focus

Brain worms: The science behind RFK Jr.'s parasitic infection

Flagship Pioneering startup Sonata Therapeutics lays off 21

First recipient of genetically engineered pig kidney has died

Study: AI not yet building 'n

Congress may force more Covid

H5N1 bird flu: what we're starting to learn about infection in cows

hotspot

entertainment

knowledge

knowledge